• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

08/25/ 2008 Email - RiaSTAP

From: Kumar, Vasantha
Sent:

Monday, August 25, 2008 12:04 PM

To: 'David.Desris@cslbehring.com'
Subject: STN.125317/0.CSL Behring. Human Fibrinogen Concentrate, Pasteurized. Riastap


Importance: High

Hi David,

The reviewer for labeling portion of the BLA would like you to provide the "Rationale for Choice of Proprietary Name".

She mentioned that a review of the study report does not include the rationale for choice of the name, RIASTAP.

So, could you please provide that to us? If you think it is already included in one of the modules, could you please specify the location?

Thanks

Vasantha

Vasantha Kumar, M.S., Ph.D.
FDA/CBER/OBRR/DBA/RPMB
Room 485N/HFM-380
1401 Rockville Pike
Rockville, MD 20852
Phone: 301-827-3524
Fax: 301-827-2857
E-Mail: vasantha.kumar@fda.hhs.gov